Gantenerumab

From Wikipedia, the free encyclopedia

Template:Cs1 config Template:Short descriptionTemplate:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Gantenerumab
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green). Template:PDB.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetBeta-amyloid (Aβ40/42)
Clinical data
ATC codePage Template:Plainlist/styles.css has no content.
  • none
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
  • Investigational
Identifiers
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC6496H10072N1740O2024S42
Molar mass146276.71 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.[1][2]

Gantenerumab binds to and clears aggregated beta amyloid fibers.[3]

A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.[6]

A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s.[7]

Gantenerumab has been further developed into trontinemab, which started a Phase III trial in 2025. Trontinemab consists of gantenerumab fused to Roche's proprietary Brainshuttle module to help it cross the blood–brain barrier.[8]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.
  2. ^ Page Module:Citation/CS1/styles.css has no content."International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID 29037101. S2CID 4795458.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi:10.1186/s13195-017-0318-y. PMC 5723032. PMID 29221491.
  5. ^ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
  6. ^ Page Module:Citation/CS1/styles.css has no content.Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, et al. (April 2025). "Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial". The Lancet. Neurology. 24 (4): 316–330. doi:10.1016/S1474-4422(25)00024-9. PMID 40120616.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Taylor E (3 October 2025). "Potential Alzheimer's treatment, trontinemab, hits the news – how does it work and is it available?". Alzheimer's Research UK. Retrieved 9 October 2025.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.


Template:Asbox Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Gantenerumab&oldid=4152931"